Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues

British Journal of Pharmacology

Volumn 172, Issue 9, 2015, Pages 2210-2218

  Sakloth, F ^a   Kolanos, R ^a   Mosier, P D ^a   Bonano, J S ^a   Banks, M L ^a   Partilla, J S ^b   Baumann, M H ^b   Negus, S S ^a   Glennon, R A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BROMOMETHCATHINONE; 4 HLOROMETHCATHINONE; 4 RIFLUOROMETHYLMETHCATHINONE; 4' METHYLMETHCATHINONE; DOPAMINE TRANSPORTER; FLEPHEDRONE; METHCATHINONE; METHCATHINONE DERIVATIVE; METHEDRONE; PSYCHOSTIMULANT AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; DAT (DOPAMINE TRANSPORTER) PROTEIN, DROSOPHILA; DROSOPHILA PROTEIN; LIGAND; MONOMETHYLPROPION; PROPIOPHENONE DERIVATIVE; PROTEIN BINDING; PSYCHOTROPIC AGENT; SLC6A4 PROTEIN, HUMAN;

ARTICLE; CHEMICAL PARAMETERS; CRYSTALLIZATION; DRUG POTENCY; HYDROPATHIC INTERACTION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; MONOAMINE RELEASE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SEQUENCE HOMOLOGY; STERIC PARAMETERS; AGONISTS; ANIMAL; BINDING SITE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HUMAN; METABOLISM; PROTEIN CONFORMATION; SELF STIMULATION;

ANIMALS; BINDING SITES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DROSOPHILA PROTEINS; DRUG DESIGN; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PROPIOPHENONES; PROTEIN BINDING; PROTEIN CONFORMATION; PSYCHOTROPIC DRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SELF STIMULATION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84926673612     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13043     Document Type: Article

References (36)

1. Abraham DJ, Kellogg GE, (1994). The effect of physical organic properties on hydrophobic fields. J Comput Aided Molec Des 8: 41-49.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Andersen J, Olsen L, Hansen KB, Taboureau O, Jorgensen FS, Jorgensen AM, et al. (2010). Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter. J Biol Chem 285: 2051-2063.
5. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
6. Baumann MH, Partilla J, Lehner KR, (2013). Psychoactive 'bath salts': not so soothing. Eur J Pharmacol 698: 1-5.
7. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, et al. (2008). The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11: 780-789.
8. Bonano JS, Banks ML, Kolanos R, Sakloth F, Barnier M, Glennon RA, et al. (2015). Quantitative structure-activity relationship (QSAR) analysis of the pharmacology of para-substituted methcathinoneanalogues. Br J Pharmacol, in press.
9. Bonano JS, Glennon RA, De Felice LJ, Banks ML, Negus SS, (2013). Abuse-related and abuse-limiting effects of methcathinone and the synthetic 'bath salts' cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology (Berl) 231: 2043-2044.
10. Celik L, Sinning S, Severinsen K, Hansen CG, Møller MS, Bols M, et al. (2008). Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. J Am Chem Soc 130: 3853-3865.
11. Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE, (1999). Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381: 63-69.
12. Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, et al. (2013). Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699: 180-187.
13. Eswar M, Marti-Renom MA, Webb B, Madhusudhan MS, Eramian D, Shen M, et al. (2007). Comparative protein structure modeling with MODELLER. Curr Protoc Protein Sci 2.9.1-2.9.31.
14. Glennon RA, (2014). Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv Pharmacol 69: 581-620.
15. Glennon RA, Yousif M, Naiman N, Kalix P, (1987). Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 26: 547-551.
16. Hansch C, Fujita T, (1995) Status of QSAR at the end of the twentieth century. In:, Hansch C, (ed.). Classical and Three-Dimensional QSAR in Agrochemistry. American Chemical Society: Washington, DC, pp. 1-12.
17. Harper KC, Bess EN, Sigman MS, (2012). Multidimensional steric parameters in the analysis of asymmetric catalytic reactions. Nat Chem 4: 366-374.
18. Huang X, Zhan C-G, (2007). How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys J 93: 3627-3639.
19. Indarte M, Madura JD, Surratt CK, (2008). Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAa leucine transporter as a template. Proteins 70: 1033-1046.
20. Jones G, Willett P, Glen RC, Leach AR, Taylor R, (1997). Development and validation of a genetic algorithm for flexible doching. J Mol Biol 267: 727-748.
21. Kaminski BJ, Griffiths RR, (1994). Intravenous self-injection of methcathinone in the baboon. Pharmacol Biochem Behav 47: 981-983.
22. Karelson M, (2000) Empirical molecular descriptors. In:, Karolson M, (ed.). Molecular Descriptors in QSAR/QSPR. Wiley-Interscience: New York, pp. 13-140.
23. Kellogg GE, Abraham DJ, (2000). Hydrophobicity: is logPo/w more than the sum of its parts? Eu J Med Chem 35: 651-661.
24. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR, (1992). Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci U S A 89: 7782-7785.
25. Koldsø H, Christiansen AB, Sinning S, Schiøtt B, (2013). Comparative modeling of the human monoamine transporters: similarities in substrate binding. ACS Chem Neurosci 4: 295-309.
26. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. (2007). Clustal W and Clustal X Version 2.0. Bioinformatics 23: 2947-2948.
27. Lee S-H, Chang M-Y, Lee KH, Park BS, Lee Y-S, Chin HR, et al. (2000). Importance of valine at position 152 for the substrate transport and 2β-carbomethoxy-3β-(4-fluorophenyl)tropane binding of dopamine transporter. Mol Pharmacol 57: 883-889.
28. Lin Z, Wang W, Kopajtic T, Rvay RS, Uhl GR, (1999). Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol Pharmacol 56: 434-447.
29. MacPhee JA, Panaye A, Dubois J-E, (1978). A critical examination of the Taft steric parameter-Es. Tetrahedron 36: 3553-3562.
30. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al. (2014). The IUPHAR/BPS guide to pharmacology: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42: 1098-1106.
31. Penmatsa A, Wang KH, Gouaux E, (2013). X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503: 85-90.
32. Severinsen K, Kraft JF, Koldsø H, Vinberg KA, Rothman RB, Partilla JS, et al. (2012). Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters. ACS Chem Neurosci 3: 693-705.
33. Taft RW, (1952). Linear free energy relationships from rates of esterification and hydrolysis of aliphatic and ortho-substituted benzoate esters. J Am Chem Soc 74: 2729-2732.
34. Taft RW, (1953). Linear steric energy relationships. J Am Chem Soc 75: 4538-4539.
35. Verloop A, Hoogenstraaten W, Tipker J, (1976) Development and application of new steric substituent parameters in drug design. In:, Ariens CJ, (ed.). Drug Design, Vol. 7. Academic Press: New York, pp. 165-207.
36. Young R, Glennon RA, (1998). Discriminative stimulus effects of S(-)-methcathinone (CAT): a potent stimulant drug of abuse. Psychopharmacology (Berl) 140: 250-256.